{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T23:15:52Z","timestamp":1794093352342,"version":"4.8.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"schweizerischer nationalfonds zur f\u00f6rderung der wissenschaftlichen forschung","doi-asserted-by":"publisher","award":["32B0-119885"],"award-info":[{"award-number":["32B0-119885"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Current treatment standards in psychiatry are oriented towards polypharmacy, that is, patients receive combinations of several antidepressants, antipsychotics, mood stabilizers, anxiolytics, hypnotics, antihistamines, and anticholinergics, along with other somatic treatments. In tandem with the beneficial effects of psychopharmacological drug treatment, patients experience significant adverse reactions which appear to have become more frequent and more severe with the rise of ubiquitous polypharmacy. In this study, we aimed to assess today\u2019s acute inpatient treatment of depressive and schizophrenic disorders with focus on therapeutic strategies, medications, adverse side effects, time course of recovery, and efficacy of treatments. Of particular interest was the weighing of the benefits and drawbacks of polypharmacy regimens. We recruited a total of 320 patients hospitalized at three residential mental health treatment centers with a diagnosis of either schizophrenic (ICD-10: \u201cF2x.x\u201d; <jats:italic>n<\/jats:italic>\u2009=\u200994; \u201cF2 patients\u201d) or depressive disorders (ICD-10: \u201cF3x.x\u201d; <jats:italic>n<\/jats:italic>\u2009=\u2009226; \u201cF3 patients\u201d). The study protocol included (1) assessment of previous history by means of the SADS Syndrome Check List SSCL-16 (lifetime version); (2) repeated measurements over 5\u00a0weeks assessing the time course of improvement by the Hamilton Depression Scale HAM-D and the Positive and Negative Syndrome Scale PANSS, along with medications and adverse side effects through the Medication and Side Effects Inventory MEDIS; and (3) the collection of blood samples from which DNA and serum were extracted. Polypharmacy was by far the most common treatment regimen (85%) in this study. On average, patients received 4.50\u2009\u00b1\u20092.68 medications, consisting of 3.30\u2009\u00b1\u20091.84 psychotropic drugs, plus 0.79\u2009\u00b1\u20091.13 medications that alleviate adverse side effects, plus 0.41\u2009\u00b1\u20090.89 other somatic medications. The treating psychiatrists appeared to be the main determining factor in this context, while \u00abprevious history\u00bb and \u00abseverity at baseline\u00bb played a minor role, if at all. Adverse drug reactions were found to be an inherent component of polypharmacy and tended to have a 2\u20133 times higher incidence compared to monotherapy. Severe adverse reactions could not be attributed to a particular drug or drug combination. Rather, the empirical data suggested that severe side effects can be triggered by virtually all combinations of drugs, provided patients have a respective vulnerability. In terms of efficacy, there were no advantages of polypharmacy over monotherapy. The results of this study underlined the fact that polypharmacy regimens are not equally suited for every patient. Specifically, such regimens appeared to have a negative impact on treatment outcome and to obfuscate the \u201cnatural\u201d time course of recovery through a multitude of interfering factors. Evidence clearly speaks against starting just every therapeutic intervention in psychiatry with a combination of psychopharmaceuticals. We think that it is time for psychiatry to reconsider its treatment strategies, which are far too one-sidedly fixated on psychopharmacology and pay far too little attention to alternative approaches, especially in mild cases where psychotherapy without concurrent medication should still be an option. Also, regular exercises and sports can definitely be an effective therapeutic means in a considerable number of cases. General practitioners (GPs) are particularly in demand here.<\/jats:p>","DOI":"10.1007\/s00406-021-01358-5","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T11:07:10Z","timestamp":1637838430000},"page":"603-619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Detailing the effects of polypharmacy in psychiatry: longitudinal study of 320 patients hospitalized for depression or schizophrenia"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6872-0619","authenticated-orcid":false,"given":"H. H.","family":"Stassen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bridler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Cattapan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Herzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Schneeberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Seifritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,25]]},"reference":[{"key":"1358_CR1","volume-title":"Fundamental facts about mental health 2016","author":"Mental Health Foundation","year":"2016","unstructured":"Mental Health Foundation (2016) Fundamental facts about mental health 2016. Mental Health Foundation, London"},{"issue":"8","key":"1358_CR2","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.4088\/JCP.v68n0805","volume":"68","author":"HH Stassen","year":"2007","unstructured":"Stassen HH, Angst J, Hell D, Scharfetter C, Szegedi A (2007) Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J Clin Psychiatry 68(8):1195\u20131205","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"1358_CR3","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.31887\/DCNS.2018.20.3\/mdavidson","volume":"20","author":"M Davidson","year":"2018","unstructured":"Davidson M (2018) The debate regarding maintenance treatment with antipsychotic drugs in schizophrenia. Dialogues Clin Neurosci 20(3):2015\u20132021","journal-title":"Dialogues Clin Neurosci"},{"issue":"5","key":"1358_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1159\/000318293","volume":"79","author":"HE Pigott","year":"2010","unstructured":"Pigott HE, Leventhal AM, Alter GS, Boren JJ (2010) Efficacy and effectiveness of antidepressants: current status of research. Psychother Psychosom 79(5):267\u2013279","journal-title":"Psychother Psychosom"},{"issue":"9","key":"1358_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.14740\/jocmr3906","volume":"11","author":"DJ Safer","year":"2019","unstructured":"Safer DJ (2019) Overprescribed medication medications for US adults: four major examples. J Clin Med Res 11(9):617\u2013622","journal-title":"J Clin Med Res"},{"key":"1358_CR6","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00406-020-01169-0","volume":"271","author":"HH Stassen","year":"2021","unstructured":"Stassen HH, Bachmann S, Bridler R, Cattapan K, Herzig D, Schneeberger A, Seifritz E (2021) Inflammatory processes linked to major depression and schizophrenic disorders and the effects of polypharmacy in psychiatry: evidence from a longitudinal study of 279 patients under therapy. Eur Arch Psychiatry Clin Neurosci 271:507\u2013520","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"4","key":"1358_CR7","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1176\/ajp.154.4.457","volume":"154","author":"GD Tollefson","year":"1997","unstructured":"Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154(4):457\u2013465","journal-title":"Am J Psychiatry"},{"issue":"Suppl. 3","key":"1358_CR8","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S0924-977X(10)70534-4","volume":"20","author":"K L\u00f6tscher","year":"2010","unstructured":"L\u00f6tscher K, Anghelescu IG, Braun S, Bridler R, Stassen HH (2010) Polypharmacy in psychiatry: clinical practice versus empirical evidence. Eur Neuropsychopharmacol 20(Suppl. 3):378\u2013379","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"1358_CR9","doi-asserted-by":"publisher","first-page":"856","DOI":"10.4088\/JCP.11r07539","volume":"73","author":"NA Khin","year":"2012","unstructured":"Khin NA, Chen YF, Yang Y, Yang P, Laughren TP (2012) Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US food and drug administration. J Clinical Psychiatry 73(6):856\u2013864","journal-title":"J Clinical Psychiatry"},{"issue":"10","key":"1358_CR10","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","volume":"174","author":"S Leucht","year":"2017","unstructured":"Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, Samara M, Rabaioli M, B\u00e4cher S, Cipriani A, Geddes JR, Salanti G, Davis JM (2017) Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry 174(10):927\u2013942","journal-title":"Am J Psychiatry"},{"key":"1358_CR11","first-page":"CD009005","volume":"6","author":"J Ortiz-Orendain","year":"2017","unstructured":"Ortiz-Orendain J, Castiello-de Obeso S, Colunga-Lozano LE, Hu Y, Maayan N, Adams CE (2017) Antipsychotic combinations for schizophrenia. Cochrane Database Syst Rev 6:CD009005","journal-title":"Cochrane Database Syst Rev"},{"key":"1358_CR12","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1001\/archpsyc.1978.01770310043002","volume":"35","author":"J Endicott","year":"1978","unstructured":"Endicott J, Spitzer RL (1978) A diagnostic interview: The Schedule for Affective Disorders and Schizophrenia (SADS). Arch Gen Psychiatry 35:837\u2013844","journal-title":"Arch Gen Psychiatry"},{"key":"1358_CR13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M (1960) A rating scale for depression (HAM-D). J Neurosurg Psychiat 23:56\u201362","journal-title":"J Neurosurg Psychiat"},{"key":"1358_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA (1987) The positive and negative symptom scale (PANSS) for schizophrenia. Schiz Bull 13:261\u2013276","journal-title":"Schiz Bull"},{"key":"1358_CR15","unstructured":"Kuny S (1988) Medication and side effects (MEDIS) among psychiatric patients under treatment. Psychiatric University Hospital Zurich: available on request"},{"key":"1358_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-68405-0","volume-title":"The AMDP System. Manual for the assessment and documentation of psychopathology","author":"W Gay","year":"1982","unstructured":"Gay W, Ban TA (1982) The AMDP System. Manual for the assessment and documentation of psychopathology. Springer, Berlin, Heidelberg, New York"},{"key":"1358_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0022-3956(98)00046-6","volume":"32","author":"J P\u00fcschel","year":"1998","unstructured":"P\u00fcschel J, Stassen HH, Bomben G, Scharfetter C, Hell D (1998) Speaking behavior and voice sound characteristics in acute schizophrenia. J Psychiatr Res 32:89\u201397","journal-title":"J Psychiatr Res"},{"key":"1358_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1017\/S0924933800001097","volume":"9","author":"HH Stassen","year":"1994","unstructured":"Stassen HH, Angst J, Delini-Stula A (1994) Severity at baseline and onset of improvement in depression. Meta-analysis of Imipramine and Moclobemide vs Placebo. Eur Psychiatry 9:129\u2013136","journal-title":"Eur Psychiatry"},{"issue":"2","key":"1358_CR19","first-page":"93","volume":"31","author":"O Agid","year":"2006","unstructured":"Agid O, Seeman P, Kapur S (2006) The \u201cdelayed onset\u201d of antipsychotic action\u2013an idea whose time has come and gone. J Psychiatry Neurosci 31(2):93\u2013100","journal-title":"J Psychiatry Neurosci"},{"key":"1358_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00406-017-0792-z","volume":"267","author":"S Braun","year":"2017","unstructured":"Braun S, Bridler R, M\u00fcller N, Schwarz MJ, Seifritz E, Weisbrod M, Zgraggen A, Stassen HH (2017) Inflammatory processes and schizophrenia: two independent lines of evidence from a study of twins discordant and concordant for schizophrenic disorders. Eur Arch Psychiatry Clin Neurosci 267:377\u2013389","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"2","key":"1358_CR21","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/schbul\/sbn018","volume":"35","author":"CU Correll","year":"2009","unstructured":"Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S (2009) Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 35(2):443\u2013457","journal-title":"Schizophr Bull"},{"key":"1358_CR22","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1017\/S1461145713000837","volume":"17","author":"HJ M\u00f6ller","year":"2014","unstructured":"M\u00f6ller HJ, Seem\u00fcller F, Schennach-Wolff R, St\u00fcbner S, R\u00fcther E, Grohmann R (2014) History, background, concepts and current use of comedication and polypharmacy in psychiatry. Int J Neuropsychopharmacol 17:983\u2013996","journal-title":"Int J Neuropsychopharmacol"},{"issue":"5","key":"1358_CR23","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jamapsychiatry.2018.4320","volume":"76","author":"J Tiihonen","year":"2019","unstructured":"Tiihonen J, Taipale H, Meht\u00e4l\u00e4 J, Vattulainen P, Correll CU, Tanskanen A (2019) Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiat 76(5):499\u2013507","journal-title":"JAMA Psychiat"},{"issue":"12","key":"1358_CR24","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1080\/17425255.2020.1821646","volume":"16","author":"JM Azorin","year":"2020","unstructured":"Azorin JM, Simon N (2020) Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale. Expert Opin Drug Metab Toxicol 16(12):1175\u20131186","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1358_CR25","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jad.2019.04.018","volume":"252","author":"TG Rhee","year":"2019","unstructured":"Rhee TG, Rosenheck RA (2019) Psychotropic polypharmacy reconsidered: Between-class polypharmacy in the context of multimorbidity in the treatment of depressive disorders. J Affect Disord 252:450\u2013457","journal-title":"J Affect Disord"},{"key":"1358_CR26","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jad.2017.11.046","volume":"227","author":"M Paulzen","year":"2018","unstructured":"Paulzen M, Haen E, Hiemke C, Fay B, Unholzer S, Gr\u00fcnder G, Schoretsanitis G (2018) Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism. J Affect Disord 227:506\u2013511","journal-title":"J Affect Disord"},{"key":"1358_CR27","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1017\/S1461145712000399","volume":"17","author":"W Fleischhacker","year":"2014","unstructured":"Fleischhacker W, Uchida H (2014) Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacology 17:1083\u20131093","journal-title":"Int J Neuropsychopharmacology"},{"issue":"3","key":"1358_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4088\/JCP.19ac13118","volume":"81","author":"D Guinart","year":"2020","unstructured":"Guinart D, Correll CU (2020) Antipsychotic polypharmacy in schizophrenia: why not? J Clin Psychiatry 81(3):19","journal-title":"J Clin Psychiatry"},{"key":"1358_CR29","first-page":"263","volume":"44","author":"HH Stassen","year":"2011","unstructured":"Stassen HH, Anghelescu IG, Angst J, B\u00f6ker H, L\u00f6tscher K, Rujescu D, Szegedi A, Scharfetter C (2011) Predicting response to psychopharmacological treatment. Survey of Recent Results Pharmacopsychiatry 44:263\u2013272","journal-title":"Survey of Recent Results Pharmacopsychiatry"},{"key":"1358_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jad.2016.03.063","volume":"202","author":"S Kvam","year":"2016","unstructured":"Kvam S, Kleppe CL, Nordhus IH, Hovland A (2016) Exercise as a treatment for depression: a meta-analysis. J Affect Disord 202:67\u201386","journal-title":"J Affect Disord"},{"issue":"1","key":"1358_CR31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/da.22842","volume":"36","author":"ID Morres","year":"2019","unstructured":"Morres ID, Hatzigeorgiadis A, Stathi A, Comoutos N, Arpin-Cribbie C, Krommidas C, Theodorakis Y (2019) Aerobic exercise for adult patients with major depressive disorder in mental health services: a systematic review and meta-analysis. Depress Anxiety 36(1):39\u201353","journal-title":"Depress Anxiety"},{"issue":"1","key":"1358_CR32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/schbul\/sbt139","volume":"40","author":"IE Sommer","year":"2014","unstructured":"Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S, Kahn RS (2014) Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull 40(1):181\u2013191","journal-title":"Schizophr Bull"},{"issue":"12","key":"1358_CR33","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1176\/appi.ajp.2014.14010094","volume":"171","author":"R Uher","year":"2014","unstructured":"Uher R, Tansey KE, Dew T, Maier W, Mors O, Hauser J, Dernovsek MZ, Henigsberg N, Souery D, Farmer A, McGuffin P (2014) An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry 171(12):1278\u20131286","journal-title":"Am J Psychiatry"},{"key":"1358_CR34","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3389\/fpsyt.2019.00458","volume":"10","author":"G Arteaga-Henr\u00edquez","year":"2019","unstructured":"Arteaga-Henr\u00edquez G, Simon MS, Burger B, Weidinger E, Wijkhuijs A, Arolt V, Birkenhager TK, Musil R, M\u00fcller N, Drexhage HA (2019) Low-grade inflammation as a predictor of antidepressant and anti-inflammatory therapy response in MDD patients: a systematic review of the literature in combination with an analysis of experimental data collected in the EU-MOODINFLAME Consortium. Front Psychiatry 10:458","journal-title":"Front Psychiatry"},{"key":"1358_CR35","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3389\/fpsyt.2019.00375","volume":"10","author":"N M\u00fcller","year":"2019","unstructured":"M\u00fcller N (2019) COX-2 inhibitors, aspirin, and other potential anti-inflammatory treatments for psychiatric disorders. Front Psychiatry 10:375","journal-title":"Front Psychiatry"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-021-01358-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-021-01358-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-021-01358-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T04:07:34Z","timestamp":1652242054000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-021-01358-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,25]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1358"],"URL":"https:\/\/doi.org\/10.1007\/s00406-021-01358-5","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,25]]},"assertion":[{"value":"25 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}